Muse Effective Treatment For Impotence In Radical Prostatectomy Patients
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Muse Effective Treatment For Impotence In Radical Prostatectomy Patients

MOUNTAIN VIEW, CA -- Oct. 21, 1998 -- Data published in this month’s issue of The Journal of Urology demonstrates that, in a clinical setting, Vivus, Inc.’s Muse(R) (alprostadil) allowed 70 percent of men with severe impotence to achieve an erection sufficient for intercourse. Of these men, 57 percent reported successful sexual intercourse during home treatment.

All 384 patients studied had undergone radical prostatectomy at least three months before study entry and had identified the surgery as the cause of their erectile dysfunction.

"I believe that Muse is an excellent treatment alternative for men after radical prostatectomy," said Ajay Nehra, M.D., assistant professor of urology, Mayo Clinic, Rochester, MN. "I would recommend Muse therapy in patients who sustain nerve injury during prostate surgery since it provides good quality erections with minimal side effects."

Each year approximately 317,000 men are diagnosed with prostate cancer. In 1996 as many as 150,000 of these men chose to treat their cancer with radical prostatectomy and this number is expected to grow with greater patient awareness and early tumour detection through the use of prostate specific antigen (PSA) level testing. Even with the incorporation of nerve-sparing surgery techniques, erectile dysfunction occurs in many patients postoperatively.

Muse therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacological agents via the urethra. Muse is applied into the urinary opening and is not for men with sickle cell trait, disease, or other blood disorders. One third of men reported genital pain, causing some to stop use. A few men reported dizziness and, less commonly, fainting.

Related Links: Muse, Vivus, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities